https://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugshttps://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugs#u28043Fri, 31 Jul 2026 17:06:18 +0000The FDA issued 30 warning letters to telehealth companies for using false or misleading claims about compounded GLP-1 products on their websites. This regulatory pressure coincides with a separate legal battle for Hims & Hers. The FTC and the states of California and Utah sued the company for allegedly sharing patient health data with advertisers and deceiving customers regarding billing, subscriptions, and cancellations. Hims & Hers has described these specific allegations as baseless.Why it mattersThe FDA targets these firms to prevent patient safety risks caused by inappropriate pro https://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugshttps://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugs#u15821Sat, 27 Jun 2026 11:01:18 +0000The FDA issued 25 warning letters to telehealth companies for misleading claims about compounded GLP-1 receptor agonists. The agency is concerned that false promotions may compromise patient safety. This action targets five specific categories of inappropriate behavior.What's confirmed:The FDA issued 25 warning letters to telehealth companies for misleading marketing of compounded GLP-1 receptor agonists.The agency identified five categories of inappropriate promotional behavior.The FDA is concerned about telehealth companies using false or misleading claims to promote compounded drugs includi https://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugshttps://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugs#u10553Tue, 23 Jun 2026 22:51:42 +0000The FDA issued 25 warning letters to telehealth companies for misleading marketing of compounded GLP-1 receptor agonists. The agency identified five categories of inappropriate promotional behavior that may compromise patient safety. These include false claims regarding FDA approval and the interchangeability of compounded drugs with approved therapies.What's confirmed:The FDA issued 25 warning letters to telehealth companies regarding misleading marketing of compounded medications.The agency targeted the promotion of compounded glucagon-like peptide-1 receptor agonists.The FDA identified five https://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugshttps://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugs#u5773Sat, 20 Jun 2026 06:51:54 +0000The US FDA sent 25 warning letters to telehealth companies making misleading claims about compounded versions of diabetes and weight loss drugs. These products target versions of medications from Novo Nordisk and Eli Lilly. A primary-source database now tracks these letters.What's confirmed:The US FDA issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of Eli Lilly and Novo Nordisk weight loss and diabetes drugs.An independently maintained database links to the original fda.gov letters issued to compounded GLP-1 telehealth provi https://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugshttps://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugs#u4501Fri, 19 Jun 2026 07:27:21 +0000The FDA is targeting telehealth companies that market compounded GLP-1 products like semaglutide and tirzepatide. Regulators are focused on false or misleading claims that suggest these compounded versions are equivalent to FDA-approved drugs. This effort is part of a broader initiative to curb misleading direct-to-consumer pharmaceutical ads.What's confirmed:The FDA issued 25 warning letters to companies marketing compounded GLP-1 products.Targeted medications include semaglutide and tirzepatide.The agency is challenging marketing claims that lead consumers to believe compounded products are https://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugshttps://www.live-feeds.com/feed/us-fda-sends-25-letters-to-telehealth-companies-over-claims-on-compounded-weight-loss-drugs#u3629Thu, 18 Jun 2026 17:03:06 +0000The US FDA sent 25 warning letters to telehealth companies for making false and misleading claims about compounded weight-loss and diabetes drugs. These copycat versions of medications from Eli Lilly and Novo Nordisk are not proven to be safe, effective, or of consistent quality. The agency is cracking down on the unauthorized marketing of these GLP-1 receptor agonist drugs.What's confirmed:The FDA issued 25 warning letters to telehealth companies for marketing false and misleading claims about compounded versions of weight loss and diabetes drugs.The warning letters targeted compounded versio